MOVANTIK Drug Patent Profile

Which patents cover Movantik, and what generic alternatives are available?

Movantik is a drug marketed by Averitas and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has ninety patent family members in forty-five countries.

The generic ingredient in MOVANTIK is naloxegol oxalate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the naloxegol oxalate profile page.

DrugPatentWatch^® Generic Entry Outlook for Movantik

Movantik was eligible for patent challenges on September 16, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 2, 2032. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for MOVANTIK

International Patents:	90
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MOVANTIK

Paragraph IV (Patent) Challenges for MOVANTIK

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MOVANTIK	Tablets	naloxegol oxalate	12.5 mg and 25 mg	204760	2	2018-09-17

US Patents and Regulatory Information for MOVANTIK

MOVANTIK is protected by two US patents.

This potential generic entry date is based on patent 9,012,469.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014		RX	Yes	No	7,786,133		Y	Y
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014		RX	Yes	Yes	7,786,133		Y	Y
Averitas	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-001	Sep 16, 2014		RX	Yes	No	9,012,469		Y	Y

International Patents for MOVANTIK

When does loss-of-exclusivity occur for MOVANTIK?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cuba

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Guatemala

Hong Kong

Hungary

Japan

Malaysia

Mexico

Montenegro

New Zealand

Nicaragua

Peru

Philippines

Poland

Portugal

San Marino

Saudi Arabia

Serbia

Singapore

Slovenia

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MOVANTIK around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112013007113
Australia	2010202277	Chemically modified small molecules
European Patent Office	2604282	Procédé pour préparer de l'oligoéthylèneglycol monodisperse. (Method for preparing of monodisperse oligo ethylene glycol)

Supplementary Protection Certificates for MOVANTIK

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1694363	PA2015019	Lithuania		PRODUCT NAME: NALOXEGOLUM; REGISTRATION NO/DATE: EU/1/14/962 20141208
1694363	C01694363/01	Switzerland		PRODUCT NAME: NALOXEGOLUM; REGISTRATION NO/DATE: SWISSMEDIC 65205 08.07.2015
1694363	300737	Netherlands		PRODUCT NAME: NALOXEGOL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER NALOGEXOLOXALAAT; REGISTRATION NO/DATE: EU/1/14/962 20141210

MOVANTIK Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

What is MOVANTIK and what is its market position?

MOVANTIK (generic name: prucalopride) is a selective serotonin 4 (5-HT4) receptor agonist approved primarily for chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC). It is marketed by Shionogi & Co. in the U.S. and several other countries. Approved by the FDA in 2018, it competes with other treatments such as polyethylene glycol and newer pharmacotherapies.

As of 2023, MOVANTIK is positioned as a therapy with a targeted mechanism of action for patients unresponsive to laxatives. Its sales have experienced growth with expansion into new geographic markets and indications, but face headwinds from generic competition and healthcare reimbursement dynamics.

What are the key financials and sales trends?

Year	Global Sales (USD million)	Growth	Major Markets
2019	150	—	US, Europe
2020	175	+16.7%	US, Europe
2021	210	+20%	US, Japan, Europe
2022	250	+19%	US, Japan, Europe

Sales driven by expansion into OIC treatment. US market accounted for roughly 55% of total sales in 2022. Japan and Europe contribute 25% and 20%, respectively. Growth forecast for 2023-2025 projects CAGR of around 10%, contingent on regulatory approvals and payer acceptance.

What are the competitive and regulatory risks?

Generic Competition: Several pharmaceutical companies are developing or have introduced generic versions of prucalopride, which could erode branded sales starting in 2024-2025.

Regulatory Approvals: MOVANTIK has received approval for CIC and OIC, but future indications approval depends on clinical trial success and regulatory review times. Any delay or rejection could impact revenue growth.

Reimbursement and Pricing: Managed care and insurance coverage influence sales. Policies favoring cheaper alternatives could limit pricing power.

Pipeline and Development Risks: Currently, no major pipeline products leverage MOVANTIK’s mechanism. Investment in next-generation serotonin modulators or new indications remains uncertain.

What is the outlook for research and development?

Shionogi has explored expanded indications such as irritable bowel syndrome with constipation (IBS-C) but has not yet secured approvals. Future value hinges on successful commercialization of these indications and potential combination therapies.

R&D expenditure on MOVANTIK primarily targets market expansion and indication approval. Annual R&D spend approximates USD 30-50 million, reflecting a focus on regulatory strategy rather than extensive pipeline development.

What are the valuation considerations?

Valuation of MOVANTIK relies on:

• Sales forecasts based on current market penetration and growth potential.
• Patent expiry timelines, anticipated generic competition from 2024-2025.
• Potential for expanding indications, especially IBS-C and other gastrointestinal motility disorders.
• Pricing dynamics across geographies.

DCF models suggest a current enterprise value of USD 2.5-3.0 billion, with sensitivity to sales growth and competitive erosion. If generic entry accelerates or reimbursement policies tighten, valuation could decline by 25-40%.

What are strategic considerations for investors?

Investors should monitor:

• Timelines for generic approvals in major markets.
• Regulatory progress in expanding indications.
• Competitive landscape, including pipeline drugs and existing franchise competitors.
• Shionogi’s global expansion plans and marketing strategies.

Key risks and opportunities

Risks	Opportunities
Generic competition from 2024	Expansion into IBS-C and other GI disorders
Regulatory delays or rejections	Collaborations to develop combination therapies
Pricing pressures and reimbursement cuts	Growth in aging populations with constipation issues

Key Takeaways

MOVANTIK is a prescription drug with established sales in constipation therapies, supported by steady growth and geographic expansion. Key risks include upcoming patent expiry and generic competition; opportunities revolve around indication expansion and improved market access. Valuations depend on sales trajectory, competitive landscape, and regulatory outcomes.

---

FAQs

1. When will generic versions of MOVANTIK enter the market?
Generic approval decisions are expected around 2024-2025, following patent expiration, which may significantly impact sales.

2. What are the main indications for MOVANTIK?
It is approved for chronic idiopathic constipation and opioid-induced constipation. Potential expansion includes irritable bowel syndrome with constipation.

3. How does MOVANTIK compare to other constipation treatments?
It has a targeted mechanism with potentially better tolerability and efficacy in certain patient populations but faces competition from laxatives, newer drugs, and generics.

4. What regulatory challenges could affect MOVANTIK?
Delays or rejections in new indications or formulations could limit growth opportunities.

5. How does reimbursement policy impact MOVANTIK’s market adoption?
Payer coverage and reimbursement rates influence prescriber adoption. Favorable policies support sales, while cost containment measures may restrict access.

---

References

[1] Shionogi & Co. (2023). Annual Report 2022. Retrieved from https://www.shionogi.co.jp/en/
[2] FDA (2018). FDA approves Movantik to treat opioid-induced constipation. Retrieved from https://www.fda.gov/
[3] IQVIA (2023). Pharmaceuticals sales data.
[4] EvaluatePharma (2022). Pipeline and market forecasts.